Article

FDA finalizes donor eligibility criteria for human tissues, cells

The FDA has established donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable diseases during transplantation.

Related Videos
2 experts in this video
2 experts in this video
Related Content
Two doctors being discussing patient history | Image Credit: © Freedomz - stock.adobe.com
February 19th 2025

Level of service for vasectomy prompts coding confusion

Jonathan Rubenstein, MD Mark Painter
"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding counseling for contraception or family planning," write Jonathan Rubenstein, MD, and Mark Painter.
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA approves Expanded Access Program to provide alternative source of BCG
February 19th 2025

FDA approves Expanded Access Program to provide alternative source of BCG

Hannah Clarke
According to ImmunityBio, shipments or rBCG are set to begin immediately via the EAP.
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
February 18th 2025

PSMA staging is linked with higher rates of ADT, ARPI utilization in prostate cancer

Benjamin P. Saylor
PSMA staging did not appear to have a significant impact on radiation therapy utilization.
Belzutifan approved in EU for renal cell carcinoma
February 18th 2025

Belzutifan approved in EU for renal cell carcinoma

Hannah Clarke
The conditional approval of belzutifan is valid for 1 year, with the opportunity for yearly renewal pending forthcoming data.
© 2025 MJH Life Sciences

All rights reserved.